MeSH term
Frequency | Condition_Probility | Animals | 95 | 0.0 |
Cells, Cultured | 25 | 0.0 |
*DNA-Binding Proteins | 5 | 0.0 |
Female | 198 | 0.0 |
*Gene Expression Regulation, Enzymologic | 3 | 0.0 |
Genes, Reporter | 6 | 0.0 |
Mice | 53 | 0.0 |
Mice, Knockout | 2 | 0.0 |
Mutation | 18 | 0.0 |
Phosphoproteins/*metabolism | 8 | 1.0 |
Promoter Regions (Genetics) | 13 | 0.0 |
Rats | 12 | 0.0 |
Rats, Wistar | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 323 | 0.0 |
Transcription Factors/*metabolism | 11 | 0.0 |
Chromosome Mapping | 12 | 0.0 |
Genetic Predisposition to Disease | 26 | 1.0 |
HLA Antigens/genetics | 16 | 5.0 |
Humans | 606 | 0.0 |
*Linkage (Genetics) | 9 | 0.0 |
Multiple Sclerosis/*genetics | 3 | 3.0 |
Base Composition | 2 | 0.0 |
Base Sequence | 107 | 0.0 |
DNA Replication | 3 | 0.0 |
In Vitro | 27 | 0.0 |
Models, Genetic | 11 | 0.0 |
Models, Molecular | 20 | 0.0 |
*Nucleic Acid Conformation | 2 | 2.0 |
Repetitive Sequences, Nucleic Acid | 8 | 0.0 |
Sequence Deletion | 4 | 0.0 |
Graft Survival | 4 | 1.0 |
HLA Antigens/analysis | 11 | 4.0 |
Kidney Transplantation/immunology/*statistics & numerical data | 3 | 30.0 |
Amino Acid Sequence | 121 | 0.0 |
Binding Sites | 33 | 0.0 |
Genome, Viral | 3 | 2.0 |
Molecular Sequence Data | 171 | 0.0 |
Tumor Cells, Cultured | 17 | 0.0 |
Adult | 136 | 0.0 |
Chi-Square Distribution | 6 | 0.0 |
HLA Antigens/*immunology | 13 | 4.0 |
Histocompatibility Testing | 44 | 5.0 |
Kidney Transplantation/immunology | 3 | 5.0 |
Logistic Models | 2 | 0.0 |
Male | 175 | 0.0 |
Phenotype | 50 | 0.0 |
Retrospective Studies | 13 | 0.0 |
Risk Factors | 27 | 0.0 |
Transplantation Immunology | 2 | 3.0 |
Alleles | 113 | 1.0 |
Cross Reactions | 14 | 1.0 |
Protein Conformation | 20 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 173 | 0.0 |
T-Lymphocytes/immunology | 27 | 1.0 |
Conserved Sequence | 4 | 0.0 |
Dose-Response Relationship, Drug | 4 | 0.0 |
Gene Expression Regulation | 5 | 0.0 |
HLA-DR Antigens/*genetics | 91 | 17.0 |
Haplotypes | 47 | 2.0 |
Interferon Type II/pharmacology | 2 | 0.0 |
Polymorphism, Genetic | 35 | 0.0 |
Transcription, Genetic | 16 | 0.0 |
Arabs/*genetics | 3 | 11.0 |
Arthritis, Juvenile Rheumatoid/*genetics | 2 | 11.0 |
Child | 45 | 0.0 |
Gene Frequency | 59 | 1.0 |
Kuwait | 2 | 8.0 |
DNA-Binding Proteins/metabolism | 6 | 0.0 |
Ligands | 6 | 0.0 |
Peroxisome Proliferators/pharmacology | 4 | 33.0 |
Promoter Regions (Genetics)/physiology | 2 | 1.0 |
Pyrimidines/pharmacology | 4 | 3.0 |
Receptors, Cytoplasmic and Nuclear/*genetics/metabolism | 3 | 10.0 |
Trans-Activation (Genetics)/drug effects | 2 | 0.0 |
Transcription Factors/*genetics/metabolism | 3 | 0.0 |
Genes, MHC Class I | 3 | 2.0 |
Genes, MHC Class II | 21 | 8.0 |
HLA Antigens/*genetics | 32 | 3.0 |
HLA-D Antigens/genetics | 5 | 12.0 |
India | 6 | 1.0 |
Linkage Disequilibrium | 5 | 0.0 |
English Abstract | 31 | 0.0 |
*Gene Frequency | 6 | 1.0 |
Genes, MHC Class II/genetics | 2 | 7.0 |
HLA-DQ Antigens/*genetics | 26 | 6.0 |
*Polymorphism, Genetic | 24 | 0.0 |
Yugoslavia | 2 | 11.0 |
Amino Acid Substitution | 3 | 0.0 |
Binding, Competitive | 13 | 0.0 |
Collagen Type II/*immunology | 2 | 40.0 |
HLA-DR Antigens/chemistry/genetics/*metabolism | 2 | 100.0 |
Hybridomas | 2 | 1.0 |
Lymphocyte Activation | 28 | 0.0 |
Receptors, Antigen, T-Cell/immunology | 3 | 1.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 22 | 0.0 |
Sequence Homology, Amino Acid | 15 | 0.0 |
Comparative Study | 84 | 0.0 |
*Immediate-Early Proteins | 2 | 0.0 |
Protein Structure, Tertiary | 4 | 0.0 |
Recombinant Fusion Proteins/chemistry/genetics/metabolism | 2 | 1.0 |
Repressor Proteins/chemistry/genetics/*metabolism | 3 | 6.0 |
*Saccharomyces cerevisiae Proteins | 5 | 0.0 |
Transcription, Genetic/*drug effects | 2 | 0.0 |
Adolescent | 53 | 0.0 |
Age of Onset | 8 | 0.0 |
*Genetic Predisposition to Disease | 5 | 0.0 |
Histocompatibility Antigens Class II/*genetics | 30 | 15.0 |
Middle Aged | 108 | 0.0 |
Multiple Sclerosis/epidemiology/*genetics | 2 | 15.0 |
Child, Preschool | 18 | 0.0 |
*HLA-DR1 Antigen | 3 | 100.0 |
Infant | 8 | 0.0 |
Recurrence | 3 | 0.0 |
Antibodies, Monoclonal/immunology | 13 | 0.0 |
Antigen Presentation | 4 | 1.0 |
Flow Cytometry | 11 | 0.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
Gene Expression | 11 | 0.0 |
Thymidine/metabolism | 2 | 0.0 |
Gene Frequency/*genetics | 2 | 1.0 |
HLA-B Antigens/genetics | 6 | 2.0 |
HLA-DQ Antigens/genetics | 16 | 6.0 |
HLA-DR Antigens/genetics | 28 | 7.0 |
Haplotypes/*genetics | 6 | 3.0 |
Polymorphism, Genetic/*genetics | 2 | 0.0 |
Cell Line | 62 | 0.0 |
Cloning, Molecular | 24 | 0.0 |
Cytotoxicity Tests, Immunologic | 5 | 1.0 |
Epitopes/immunology | 12 | 2.0 |
HLA Antigens/immunology | 5 | 2.0 |
Lymphocyte Activation/drug effects | 3 | 0.0 |
Molecular Mimicry | 2 | 2.0 |
T-Lymphocytes/*immunology | 45 | 2.0 |
T-Lymphocytes, Cytotoxic/*immunology | 6 | 1.0 |
Cell Nucleus/chemistry | 2 | 1.0 |
Two-Hybrid System Techniques | 2 | 0.0 |
Arthritis, Rheumatoid/*genetics | 12 | 16.0 |
Disease Progression | 4 | 0.0 |
DNA/genetics/metabolism | 2 | 0.0 |
Oligopeptides/pharmacology | 2 | 1.0 |
Promoter Regions (Genetics)/genetics | 4 | 0.0 |
Protein Binding | 26 | 0.0 |
Templates, Genetic | 2 | 1.0 |
Transcription, Genetic/drug effects | 3 | 0.0 |
Genetic Predisposition to Disease/genetics | 3 | 0.0 |
HLA-DR1 Antigen/genetics | 11 | 68.0 |
Aged | 61 | 0.0 |
HLA-DR1 Antigen/*genetics | 11 | 64.0 |
Japan | 9 | 0.0 |
Schizophrenia/*genetics | 3 | 1.0 |
HLA-D Antigens/genetics/*immunology | 2 | 28.0 |
HLA-DR Antigens/genetics/*immunology/metabolism | 3 | 75.0 |
Kinetics | 9 | 0.0 |
Peptides/chemistry/immunology | 2 | 5.0 |
Spectrometry, Fluorescence | 2 | 0.0 |
Arthritis, Rheumatoid/genetics/*immunology/physiopathology | 2 | 66.0 |
Epitopes | 21 | 2.0 |
Genotype | 39 | 0.0 |
Great Britain | 4 | 1.0 |
Spain | 4 | 1.0 |
Time Factors | 9 | 0.0 |
Genes, Dominant | 2 | 0.0 |
*Genes, MHC Class II | 39 | 12.0 |
L Cells (Cell Line) | 9 | 3.0 |
Peptide Fragments/genetics/*immunology/metabolism | 2 | 33.0 |
Transfection | 28 | 0.0 |
*Major Histocompatibility Complex | 16 | 5.0 |
Testosterone/*blood | 2 | 0.0 |
Tumor Necrosis Factor-alpha/genetics/physiology | 2 | 33.0 |
Case-Control Studies | 12 | 0.0 |
Jews/*genetics | 3 | 2.0 |
Odds Ratio | 6 | 0.0 |
Cohort Studies | 7 | 0.0 |
*Ethnic Groups | 2 | 1.0 |
European Continental Ancestry Group | 7 | 1.0 |
Forecasting | 2 | 0.0 |
Hispanic Americans | 2 | 3.0 |
Longitudinal Studies | 3 | 0.0 |
United States | 4 | 0.0 |
DNA Primers/genetics | 6 | 0.0 |
RNA, Messenger/genetics/metabolism | 3 | 0.0 |
Rats, Sprague-Dawley | 2 | 0.0 |
Receptors, Cytoplasmic and Nuclear/genetics/*metabolism | 3 | 6.0 |
Transcription Factors/genetics/*metabolism | 5 | 0.0 |
Heterozygote Detection | 2 | 0.0 |
*Chromosomes, Human, Pair 1 | 3 | 0.0 |
DNA-Binding Proteins/genetics | 2 | 0.0 |
Transcription Factors/genetics | 2 | 0.0 |
Liver/metabolism | 2 | 0.0 |
Receptors, Retinoic Acid/metabolism | 2 | 2.0 |
*Regulatory Sequences, Nucleic Acid | 3 | 0.0 |
Retinoid X Receptors | 15 | 5.0 |
Species Specificity | 7 | 0.0 |
Trans-Activation (Genetics) | 5 | 0.0 |
Antigen-Presenting Cells/immunology | 9 | 3.0 |
Peptide Fragments/immunology | 6 | 2.0 |
Peptides/*immunology/metabolism | 3 | 25.0 |
Age Factors | 11 | 0.0 |
Diabetes Mellitus, Type 1/*genetics | 3 | 1.0 |
Sex Factors | 9 | 0.0 |
*Alleles | 23 | 1.0 |
Continental Population Groups/*genetics | 2 | 4.0 |
HLA-A Antigens/genetics | 3 | 1.0 |
HLA-B Antigens/*genetics | 2 | 0.0 |
HLA-C Antigens/genetics | 3 | 3.0 |
Reference Values | 8 | 0.0 |
DNA Primers | 8 | 0.0 |
DNA-Binding Proteins/*metabolism | 5 | 0.0 |
Recombinant Proteins/metabolism | 4 | 0.0 |
*Transcription, Genetic | 5 | 0.0 |
Arthritis, Rheumatoid/*genetics/immunology | 14 | 29.0 |
Prospective Studies | 8 | 0.0 |
Antibodies | 2 | 0.0 |
Arthritis, Rheumatoid/*immunology | 11 | 5.0 |
Collagen/*immunology | 2 | 10.0 |
Disease Susceptibility/*immunology | 2 | 33.0 |
Arthritis, Rheumatoid/epidemiology/*genetics/immunology | 2 | 50.0 |
HLA-DR4 Antigen/genetics | 8 | 27.0 |
Prevalence | 6 | 0.0 |
Aged, 80 and over | 19 | 0.0 |
Autoantibodies/analysis | 5 | 2.0 |
Autoimmune Diseases/*immunology | 2 | 1.0 |
Chronic Disease | 2 | 0.0 |
HLA Antigens/*blood | 2 | 7.0 |
Prognosis | 9 | 0.0 |
European Continental Ancestry Group/genetics | 5 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 6 | 0.0 |
HLA-DR1 Antigen/*metabolism | 7 | 87.0 |
Structure-Activity Relationship | 12 | 0.0 |
HLA-DR1 Antigen/genetics/*immunology | 2 | 50.0 |
Leukocytes/immunology | 2 | 1.0 |
B-Lymphocytes/immunology | 18 | 2.0 |
Italy | 6 | 0.0 |
Polymerase Chain Reaction | 40 | 0.0 |
Histocompatibility Antigens Class II/analysis | 8 | 4.0 |
Myasthenia Gravis/chemically induced/*immunology | 2 | 100.0 |
Protein Binding/immunology | 4 | 2.0 |
HLA-DR Antigens/analysis | 24 | 3.0 |
Tuberculin/immunology | 2 | 3.0 |
Genetic Markers | 22 | 0.0 |
Linkage (Genetics) | 23 | 0.0 |
Pedigree | 27 | 0.0 |
HLA Antigens/genetics/*immunology | 3 | 4.0 |
Spain/epidemiology | 2 | 1.0 |
*Variation (Genetics) | 3 | 0.0 |
3T3 Cells | 3 | 0.0 |
DNA, Viral | 2 | 1.0 |
Arthritis, Rheumatoid/genetics | 3 | 27.0 |
Asian Continental Ancestry Group/*genetics | 2 | 0.0 |
Antigen-Presenting Cells | 2 | 10.0 |
HLA-DR Antigens/*genetics/immunology | 11 | 21.0 |
Point Mutation | 3 | 0.0 |
Evolution, Molecular | 2 | 0.0 |
Gorilla gorilla | 3 | 7.0 |
Pan troglodytes | 3 | 2.0 |
Recombination, Genetic | 6 | 0.0 |
Sequence Alignment | 10 | 0.0 |
Arthritis, Rheumatoid/*immunology/pathology | 2 | 6.0 |
Heat-Shock Proteins 70/*immunology | 2 | 33.0 |
Immunoglobulin M/blood | 2 | 1.0 |
Genes, MHC Class II/*genetics | 4 | 5.0 |
Immunoglobulin Variable Region/genetics | 2 | 1.0 |
HLA-DR1 Antigen/*chemistry | 2 | 100.0 |
Histocompatibility Antigens Class II/genetics | 6 | 5.0 |
HLA-DR4 Antigen/*genetics/immunology | 2 | 50.0 |
Mice, Transgenic | 5 | 0.0 |
Variation (Genetics) | 12 | 0.0 |
Arthritis, Rheumatoid/*drug therapy | 3 | 6.0 |
Epitopes/genetics | 8 | 9.0 |
*Histocompatibility Antigens Class II | 7 | 11.0 |
Italy/epidemiology | 2 | 0.0 |
Dimerization | 5 | 0.0 |
Gene Expression Regulation/drug effects | 2 | 0.0 |
RNA, Messenger/metabolism | 4 | 0.0 |
Receptors, Retinoic Acid/genetics/metabolism | 2 | 6.0 |
Autoantibodies/*immunology | 2 | 0.0 |
HLA-DR1 Antigen/*immunology | 7 | 77.0 |
Escherichia coli | 4 | 0.0 |
Heat | 3 | 0.0 |
Macromolecular Substances | 16 | 0.0 |
*Protein Conformation | 4 | 1.0 |
Binding Sites/genetics | 3 | 0.0 |
COS Cells | 3 | 0.0 |
HLA-DR1 Antigen/metabolism | 4 | 100.0 |
Recombinant Proteins/chemistry/genetics/metabolism | 3 | 0.0 |
Solubility | 2 | 0.0 |
Hepatitis B virus/*genetics | 5 | 16.0 |
Polymerase Chain Reaction/*methods | 5 | 0.0 |
Tretinoin/*metabolism | 2 | 4.0 |
Brazil | 2 | 0.0 |
HLA-A Antigens/*genetics | 2 | 1.0 |
*Haplotypes | 9 | 3.0 |
Consensus Sequence | 4 | 0.0 |
Peptide Fragments/metabolism | 2 | 0.0 |
Regulatory Sequences, Nucleic Acid | 2 | 0.0 |
CD4-Positive T-Lymphocytes/*immunology | 8 | 1.0 |
Clone Cells | 21 | 1.0 |
Cytotoxicity, Immunologic | 6 | 0.0 |
Recombinant Proteins/immunology | 3 | 0.0 |
Antibodies, Monoclonal | 8 | 0.0 |
Antigen-Presenting Cells/*immunology | 5 | 3.0 |
Cell Line, Transformed | 10 | 0.0 |
HLA-D Antigens/immunology | 2 | 5.0 |
DNA/*metabolism | 3 | 0.0 |
Drug Stability | 2 | 0.0 |
Disease Susceptibility | 40 | 5.0 |
European Continental Ancestry Group/*genetics | 2 | 0.0 |
Immunoglobulin E/blood | 2 | 1.0 |
Immunophenotyping | 8 | 0.0 |
Polymerase Chain Reaction/methods | 5 | 0.0 |
Genome, Human | 2 | 0.0 |
Predictive Value of Tests | 2 | 0.0 |
Blotting, Northern | 4 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 13 | 0.0 |
Hamsters | 2 | 0.0 |
Recombinant Proteins/genetics/metabolism | 3 | 0.0 |
Signal Transduction | 3 | 0.0 |
*Vaccination | 2 | 3.0 |
DNA, Complementary | 4 | 0.0 |
Exons | 6 | 0.0 |
Introns | 4 | 0.0 |
Phylogeny | 3 | 0.0 |
DNA, Viral/biosynthesis | 2 | 3.0 |
Hepatitis B Core Antigens/genetics | 2 | 33.0 |
Protein Processing, Post-Translational | 2 | 0.0 |
Spodoptera | 3 | 1.0 |
Arthritis/genetics | 2 | 50.0 |
Heterozygote | 14 | 0.0 |
Homozygote | 20 | 1.0 |
HLA-DR Antigens/*immunology/metabolism | 2 | 66.0 |
Arthritis, Rheumatoid/immunology/metabolism | 2 | 20.0 |
HLA-DR Antigens/*metabolism | 11 | 18.0 |
Leukocytes, Mononuclear/immunology | 2 | 0.0 |
Lymphocyte Activation/immunology | 6 | 1.0 |
HLA-DR1 Antigen/*analysis/genetics | 3 | 100.0 |
HLA-DR4 Antigen/*analysis/genetics | 2 | 100.0 |
Israel/ethnology | 2 | 20.0 |
Severity of Illness Index | 7 | 0.0 |
Arthritis, Rheumatoid/*genetics/*immunology | 5 | 23.0 |
Continental Population Groups | 2 | 1.0 |
Family Health | 3 | 0.0 |
*Evolution, Molecular | 2 | 0.0 |
Haplotypes/genetics | 5 | 0.0 |
Multigene Family | 2 | 0.0 |
*Repetitive Sequences, Nucleic Acid | 2 | 0.0 |
DNA/analysis | 6 | 0.0 |
HLA-DR Antigens/*analysis/genetics | 10 | 40.0 |
Incidence | 4 | 0.0 |
Polymorphism, Restriction Fragment Length | 34 | 1.0 |
Transcription Factors/*genetics | 4 | 0.0 |
Antirheumatic Agents/therapeutic use | 2 | 6.0 |
Greece/epidemiology | 2 | 5.0 |
Survival Rate | 3 | 0.0 |
Treatment Outcome | 4 | 0.0 |
Receptors, Cytoplasmic and Nuclear/*metabolism | 5 | 3.0 |
Disease Susceptibility/immunology | 4 | 5.0 |
Oligonucleotide Probes | 9 | 1.0 |
Sequence Analysis, DNA | 5 | 0.0 |
Histocompatibility Antigens Class II/*metabolism | 3 | 5.0 |
*Antigen Presentation | 3 | 1.0 |
Hydrogen-Ion Concentration | 2 | 0.0 |
Chloramphenicol O-Acetyltransferase/biosynthesis | 4 | 2.0 |
Protein Biosynthesis | 4 | 0.0 |
Rabbits | 2 | 0.0 |
Receptors, Retinoic Acid/*metabolism | 3 | 5.0 |
Xenopus | 2 | 0.0 |
Biopsy | 3 | 0.0 |
Hand | 2 | 7.0 |
Rheumatoid Factor/*blood | 3 | 16.0 |
Tretinoin/*pharmacology | 4 | 1.0 |
HLA-DR Antigens/*analysis | 15 | 8.0 |
Autoimmunity/physiology | 2 | 28.0 |
RNA Polymerase II/*metabolism | 2 | 2.0 |
Antibody Formation | 3 | 0.0 |
B-Lymphocytes/*immunology | 5 | 0.0 |
Immunity, Cellular | 4 | 0.0 |
*Exons | 3 | 0.0 |
Bacterial Proteins/*immunology | 3 | 10.0 |
*Epitopes | 6 | 4.0 |
Mycobacterium leprae/*immunology | 2 | 6.0 |
Oocytes/physiology | 2 | 1.0 |
Phosphoproteins/*genetics | 5 | 2.0 |
RNA, Messenger/genetics | 4 | 0.0 |
TATA-Box Binding Protein | 8 | 2.0 |
Gene Expression Regulation, Fungal | 2 | 2.0 |
Genetic Complementation Test | 2 | 0.0 |
Mycobacterium leprae/immunology | 2 | 9.0 |
Fungal Proteins/genetics | 2 | 1.0 |
Mutagenesis, Site-Directed | 5 | 0.0 |
Peptides/*metabolism | 4 | 2.0 |
*Genes, MHC Class I | 3 | 1.0 |
Carcinoma, Hepatocellular | 2 | 0.0 |
Cercopithecus aethiops | 3 | 0.0 |
Liver Neoplasms | 2 | 0.0 |
Recombinant Proteins/biosynthesis | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 6 | 0.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
*TATA Box | 2 | 1.0 |
Hela Cells | 9 | 0.0 |
Saccharomyces cerevisiae | 2 | 0.0 |
HLA-D Antigens/*metabolism | 3 | 14.0 |
Herpesvirus 4, Human | 3 | 2.0 |
Liver Diseases/*immunology | 2 | 10.0 |
Major Histocompatibility Complex/*genetics | 4 | 2.0 |
HLA-DQ Antigens/*analysis | 5 | 29.0 |
*Genome, Viral | 2 | 2.0 |
Mutagenesis | 2 | 0.0 |
Trans-Activators/genetics | 3 | 1.0 |
Finland | 4 | 1.0 |
Peptide Mapping | 4 | 0.0 |
Transcription Factor TFIIA | 3 | 5.0 |
Histocompatibility | 3 | 2.0 |
Pregnancy | 4 | 0.0 |
DNA/metabolism | 2 | 0.0 |
Phosphorylation | 2 | 0.0 |
*Promoter Regions (Genetics) | 5 | 0.0 |
TATA Box | 5 | 1.0 |
HLA-DR Antigens/analysis/genetics | 6 | 23.0 |
Immunogenetics | 5 | 10.0 |
Rheumatoid Factor/*analysis | 2 | 9.0 |
HLA-DQ Antigens/*analysis/genetics | 3 | 18.0 |
Epitopes/chemistry | 2 | 2.0 |
HLA-DR Antigens/genetics/immunology | 2 | 6.0 |
Influenza A Virus, Human/immunology | 3 | 12.0 |
Major Histocompatibility Complex | 9 | 3.0 |
Cell Division | 5 | 0.0 |
*Family Health | 2 | 3.0 |
Crystallography, X-Ray | 5 | 0.0 |
Antigens, Viral/*immunology | 2 | 2.0 |
HLA-DR Antigens/genetics/*immunology | 8 | 24.0 |
Risk | 5 | 0.0 |
Blotting, Southern | 10 | 0.0 |
Chickens | 2 | 0.0 |
*Chromosome Mapping | 2 | 0.0 |
*Gene Expression Regulation | 3 | 0.0 |
Nuclear Proteins/metabolism | 2 | 0.0 |
Chile/epidemiology | 2 | 11.0 |
HLA-D Antigens/blood | 2 | 50.0 |
Arthritis, Rheumatoid/ethnology/*immunology | 2 | 66.0 |
Korea | 3 | 1.0 |
Oligonucleotide Probes/genetics | 3 | 2.0 |
Autoantibodies/immunology | 2 | 1.0 |
HLA-D Antigens/*immunology | 5 | 8.0 |
HLA-DQ Antigens/analysis | 5 | 10.0 |
Regression Analysis | 6 | 0.0 |
Oligodeoxyribonucleotides/chemistry | 4 | 1.0 |
Repressor Proteins/genetics | 2 | 1.0 |
Histocompatibility Testing/*methods | 7 | 4.0 |
*Polymorphism, Restriction Fragment Length | 12 | 1.0 |
Molecular Weight | 8 | 0.0 |
Restriction Mapping | 6 | 0.0 |
Nucleic Acid Conformation | 2 | 0.0 |
Plasmids | 4 | 0.0 |
Receptors, Retinoic Acid/biosynthesis/*metabolism | 2 | 50.0 |
Transcription Factors/biosynthesis/*metabolism | 2 | 4.0 |
HLA-DP Antigens/genetics | 4 | 8.0 |
Lymphocytes/immunology | 5 | 1.0 |
HLA-DP Antigens/*genetics | 4 | 4.0 |
Polymerase Chain Reaction/statistics & numerical data | 2 | 33.0 |
RNA-Directed DNA Polymerase/*metabolism | 2 | 50.0 |
*Histocompatibility Testing | 5 | 2.0 |
Steroid 21-Hydroxylase/*genetics | 3 | 4.0 |
HLA-DR1 Antigen/*chemistry/metabolism | 2 | 66.0 |
Hemagglutinin Glycoproteins, Influenza Virus | 5 | 29.0 |
Peptides/metabolism | 2 | 0.0 |
Transcription Factor TFIIB | 3 | 3.0 |
Epitope Mapping | 2 | 0.0 |
Histocompatibility Antigens Class II/metabolism | 2 | 2.0 |
T-Lymphocytes, Helper-Inducer/*immunology | 3 | 1.0 |
France | 3 | 1.0 |
Oligodeoxyribonucleotides | 3 | 0.0 |
*Antigens, Differentiation, B-Lymphocyte | 2 | 13.0 |
Histocompatibility Antigens Class II/*chemistry | 3 | 42.0 |
Kidney Transplantation/*immunology | 6 | 2.0 |
Cadaver | 4 | 1.0 |
Tissue Donors | 5 | 1.0 |
*Bacterial Toxins | 2 | 1.0 |
Receptors, Antigen, T-Cell/metabolism | 2 | 1.0 |
Gene Library | 2 | 0.0 |
Gene Frequency/genetics | 2 | 0.0 |
Genetics, Population | 3 | 0.0 |
African Continental Ancestry Group/*genetics | 2 | 0.0 |
*Oligonucleotide Probes | 2 | 8.0 |
Genetic Vectors | 4 | 0.0 |
Phosphoproteins/genetics/*metabolism | 2 | 1.0 |
Arthritis, Rheumatoid/genetics/*immunology | 10 | 27.0 |
Norway | 2 | 1.0 |
*Cytotoxicity, Immunologic | 4 | 0.0 |
HIV-1/*immunology | 2 | 0.0 |
T-Lymphocytes, Cytotoxic/immunology | 5 | 1.0 |
Turkey | 2 | 1.0 |
Diabetes Mellitus, Type 1/*genetics/immunology | 4 | 7.0 |
Antigens, Viral/immunology | 2 | 1.0 |
Fibroblasts/immunology | 3 | 4.0 |
HLA-DR1 Antigen/immunology | 4 | 80.0 |
Histocompatibility Antigens Class II/*physiology | 2 | 9.0 |
Precipitin Tests | 2 | 0.0 |
B-Lymphocytes | 2 | 1.0 |
Cell Division/drug effects | 2 | 0.0 |
Models, Structural | 2 | 1.0 |
HLA-DR1 Antigen/chemistry/*immunology | 2 | 66.0 |
Peptide Fragments/*metabolism | 3 | 2.0 |
HLA-DR4 Antigen/*analysis | 3 | 33.0 |
Allergens/*immunology | 2 | 2.0 |
HLA-DQ Antigens/genetics/*immunology | 2 | 15.0 |
Skin Tests | 2 | 1.0 |
Mice, Inbred BALB C | 4 | 0.0 |
DNA/analysis/genetics | 3 | 2.0 |
HLA-DR Antigens/*analysis/genetics/immunology | 2 | 40.0 |
Staphylococcus aureus/immunology | 2 | 1.0 |
Clone Cells/immunology | 11 | 7.0 |
Antibodies/analysis | 4 | 3.0 |
Antibody Specificity | 11 | 0.0 |
Centromere/immunology | 3 | 27.0 |
Germany/epidemiology | 2 | 1.0 |
Scleroderma, Systemic/genetics/*immunology | 2 | 28.0 |
HLA Antigens/*analysis/genetics/immunology | 2 | 22.0 |
Reproducibility of Results | 2 | 0.0 |
Sensitivity and Specificity | 2 | 0.0 |
Penicillamine/adverse effects | 2 | 33.0 |
HLA-DR3 Antigen/*metabolism | 2 | 100.0 |
Rheumatoid Factor/analysis | 3 | 4.0 |
HLA-D Antigens/*genetics | 27 | 18.0 |
Epitopes/*genetics/immunology | 3 | 21.0 |
HLA-D Antigens/genetics/immunology | 2 | 50.0 |
HLA-DR1 Antigen/genetics/immunology | 3 | 60.0 |
HLA-DR4 Antigen/genetics/immunology | 2 | 50.0 |
*Models, Genetic | 2 | 1.0 |
Antibodies, Monoclonal/*immunology | 4 | 0.0 |
HLA-DR Antigens/*immunology | 12 | 9.0 |
Mice, Inbred BALB C/immunology | 3 | 9.0 |
Genes, Structural | 9 | 1.0 |
*DNA Replication | 3 | 1.0 |
Epitopes/analysis | 7 | 2.0 |
Virus Replication | 4 | 0.0 |
Gene Expression/genetics | 2 | 0.0 |
Antigens, CD8/analysis | 2 | 0.0 |
Immune Tolerance | 3 | 1.0 |
Immunization | 5 | 1.0 |
DNA/genetics | 15 | 0.0 |
HLA-DR4 Antigen/*genetics | 7 | 23.0 |
Mathematics | 3 | 1.0 |
DNA Restriction Enzymes | 11 | 2.0 |
Evaluation Studies | 3 | 0.0 |
Gene Amplification | 5 | 0.0 |
*Antibodies, Monoclonal | 3 | 1.0 |
Epitopes/genetics/immunology | 3 | 8.0 |
HLA-DR2 Antigen/*genetics | 4 | 20.0 |
*Recombination, Genetic | 4 | 1.0 |
Graft Survival/*immunology | 2 | 3.0 |
*Histocompatibility | 2 | 3.0 |
Epitopes/*metabolism | 2 | 10.0 |
Autoimmune Diseases/*genetics/immunology | 2 | 11.0 |
Histocompatibility Antigens Class II/*genetics/immunology | 2 | 10.0 |
Follow-Up Studies | 5 | 0.0 |
Lymphocyte Culture Test, Mixed | 11 | 1.0 |
*Tissue Donors | 3 | 2.0 |
*Graft Survival | 4 | 2.0 |
Infant, Newborn | 3 | 0.0 |
Antigens, Protozoan/*immunology | 2 | 5.0 |
Immunoblotting | 3 | 0.0 |
Plasmodium falciparum/*immunology | 2 | 4.0 |
Nucleic Acid Hybridization | 15 | 0.0 |
Bone Marrow Transplantation/immunology | 2 | 5.0 |
DNA Probes | 6 | 0.0 |
Cytotoxicity, Immunologic/immunology | 2 | 2.0 |
HLA-DR Antigens/immunology | 3 | 1.0 |
Peptide Fragments/chemical synthesis/immunology | 2 | 16.0 |
Arthritis, Rheumatoid/genetics/immunology | 3 | 25.0 |
Antigens, Bacterial/*immunology | 4 | 3.0 |
Heat-Shock Proteins/*immunology | 2 | 16.0 |
HLA-DR Antigens/*physiology | 2 | 28.0 |
Hemagglutinins, Viral/immunology | 3 | 30.0 |
Isoantigens/*immunology | 2 | 2.0 |
Antigen-Antibody Reactions | 4 | 1.0 |
Hemagglutinins, Viral/*immunology | 3 | 25.0 |
HLA-B27 Antigen/*genetics | 2 | 10.0 |
Leukocyte Count | 3 | 0.0 |
Neutrophils/immunology | 2 | 1.0 |
Blotting, Western | 3 | 0.0 |
DNA | 2 | 0.0 |
Receptors, Antigen, T-Cell/*immunology | 5 | 2.0 |
Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 2 | 2.0 |
Arthritis, Rheumatoid/immunology | 4 | 4.0 |
*Transfection | 2 | 0.0 |
HLA-DR Antigens/genetics/*metabolism | 2 | 28.0 |
*Lymphocyte Activation | 4 | 0.0 |
Penicillamine/*adverse effects/therapeutic use | 2 | 28.0 |
Dose-Response Relationship, Immunologic | 2 | 0.0 |
HLA Antigens/*analysis/genetics | 8 | 8.0 |
Autoantibodies/*analysis | 6 | 2.0 |
Scleroderma, Systemic/*immunology | 3 | 11.0 |
Receptors, Antigen, T-Cell, alpha-beta/*genetics | 3 | 4.0 |
HLA-DR Antigens/genetics/metabolism | 2 | 18.0 |
Molecular Conformation | 5 | 2.0 |
Protein Denaturation/immunology | 2 | 40.0 |
Evolution | 4 | 1.0 |
HLA-DR1 Antigen/analysis | 4 | 57.0 |
HLA-DR4 Antigen/analysis | 3 | 16.0 |
Oligonucleotides/analysis | 2 | 25.0 |
Complement 4/genetics | 3 | 4.0 |
Tumor Necrosis Factor-alpha/genetics | 2 | 0.0 |
Herpesvirus 4, Human/immunology | 2 | 2.0 |
Analysis of Variance | 2 | 0.0 |
Chromosome Aberrations | 2 | 0.0 |
Chromosome Deletion | 2 | 0.0 |
DNA, Viral/*genetics | 2 | 2.0 |
Hepatitis B virus/*genetics/physiology | 2 | 66.0 |
Antibodies, Monoclonal/diagnostic use | 8 | 0.0 |
Circular Dichroism | 2 | 0.0 |
T-Lymphocytes, Helper-Inducer/immunology | 3 | 1.0 |
Epitopes/*analysis | 5 | 3.0 |
DNA/*genetics | 3 | 0.0 |
Diabetes Mellitus, Type 1/genetics/*immunology | 3 | 6.0 |
Arthritis, Juvenile Rheumatoid/*genetics/immunology | 2 | 40.0 |
Glycine/analysis | 2 | 50.0 |
Chromatography, Affinity | 4 | 0.0 |
Chromatography, Gel | 2 | 0.0 |
HLA Antigens/*analysis | 19 | 4.0 |
Hepatitis Viruses/*genetics | 2 | 100.0 |
England | 3 | 2.0 |
Epitopes/*immunology | 2 | 0.0 |
HLA-D Antigens/*analysis | 12 | 19.0 |
India/ethnology | 3 | 4.0 |
Drug Resistance | 2 | 0.0 |
HLA-DR5 Antigen/immunology | 2 | 66.0 |
Codon/genetics | 2 | 0.0 |
Tetanus Toxoid/immunology | 2 | 2.0 |
DNA, Viral/*analysis | 3 | 3.0 |
African Continental Ancestry Group | 2 | 0.0 |
Asian Continental Ancestry Group | 3 | 1.0 |
Jews | 2 | 2.0 |
Complement Factor B/*genetics | 3 | 2.0 |
Epidemiologic Methods | 2 | 3.0 |
Steroid 21-Hydroxylase/genetics | 5 | 11.0 |
Georgia (Republic) | 2 | 28.0 |
HLA Antigens/analysis/*genetics | 2 | 5.0 |
17-alpha-Hydroxyprogesterone | 4 | 9.0 |
*Adrenal Hyperplasia, Congenital | 3 | 13.0 |
Hydroxyprogesterones/blood | 4 | 8.0 |
Steroid Hydroxylases/*deficiency | 9 | 32.0 |
HLA Antigens/analysis/classification | 2 | 40.0 |
Immunohistochemistry | 2 | 0.0 |
Autoradiography | 2 | 0.0 |
HLA-B Antigens/analysis | 5 | 4.0 |
HLA-C Antigens/analysis | 5 | 10.0 |
HLA-DR7 Antigen/analysis | 2 | 100.0 |
*Genes, Viral | 3 | 1.0 |
Gene Conversion | 3 | 5.0 |
Antigens | 2 | 2.0 |
Cell Separation | 2 | 0.0 |
HLA-DR Antigens | 40 | 11.0 |
HLA-D Antigens/analysis | 2 | 3.0 |
Hepatitis B/*immunology | 2 | 6.0 |
Immunoglobulin Allotypes/analysis | 2 | 22.0 |
Isoelectric Focusing | 3 | 0.0 |
Neuraminidase | 2 | 5.0 |
HLA-A Antigens/analysis | 4 | 4.0 |
Russia | 2 | 2.0 |
Probability | 2 | 0.0 |
Taiwan | 2 | 1.0 |
*Genes, Structural | 7 | 0.0 |
*IgA Deficiency | 2 | 11.0 |
Influenza A Virus, Human/*immunology | 6 | 20.0 |
Viral Matrix Proteins/*immunology | 2 | 12.0 |
Arthritis, Rheumatoid/*etiology/genetics/immunology | 2 | 66.0 |
HLA-DR4 Antigen | 15 | 25.0 |
Immunoglobulin Allotypes/*immunology | 2 | 25.0 |
Histocompatibility Antigens Class II/*immunology | 13 | 7.0 |
Cell Transformation, Viral | 5 | 1.0 |
HLA-DQ Antigens/*immunology | 2 | 14.0 |
Immunoglobulin M/immunology | 2 | 1.0 |
*Mutation | 5 | 0.0 |
Steroid Hydroxylases/*genetics | 2 | 2.0 |
*Kidney Transplantation | 4 | 0.0 |
Crossing Over, Genetic | 2 | 2.0 |
Pseudogenes | 2 | 1.0 |
Diagnosis, Differential | 2 | 0.0 |
*HLA-DR Antigens | 5 | 35.0 |
Receptors, Antigen, T-Cell/genetics | 3 | 3.0 |
Diabetes Mellitus, Type 1/epidemiology/*genetics | 2 | 9.0 |
*Adrenal Hyperplasia, Congenital/genetics | 3 | 100.0 |
*HLA Antigens | 2 | 0.0 |
*HLA-B Antigens | 5 | 8.0 |
*HLA-D Antigens | 2 | 28.0 |
HLA-DR1 Antigen | 33 | 91.0 |
Nasopharyngeal Neoplasms/*immunology | 2 | 22.0 |
HLA-DR2 Antigen | 3 | 15.0 |
Leprosy/*genetics | 2 | 22.0 |
Epitopes/genetics/immunology/isolation & purification | 2 | 100.0 |
HLA-DR Antigens/*genetics/immunology/isolation & purification | 2 | 100.0 |
Complement/analysis | 2 | 1.0 |
Kidney Transplantation | 2 | 1.0 |
Epitopes/*genetics | 2 | 6.0 |
Fluorescent Antibody Technique | 5 | 0.0 |
*Genetic Markers | 2 | 0.0 |
HLA-B8 Antigen | 3 | 11.0 |
HLA-DR3 Antigen | 4 | 10.0 |
HLA-DR7 Antigen | 4 | 30.0 |
Kidney Transplantation/*immunology/statistics & numerical data | 2 | 11.0 |
*Deoxyribonucleases, Type II Site-Specific | 2 | 3.0 |
Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase | 2 | 6.0 |
Complement 4/*genetics | 3 | 2.0 |
Complement 4a | 2 | 3.0 |
Isoantigens/immunology | 3 | 3.0 |
Denmark | 2 | 1.0 |
Hepatitis B virus/genetics/*physiology | 2 | 33.0 |
Epitopes/analysis/genetics | 2 | 66.0 |
Haploidy | 7 | 5.0 |
*Thiazolidinediones | 2 | 2.0 |
Deoxyribonuclease EcoRI | 2 | 4.0 |
HLA-B Antigens | 16 | 4.0 |
HLA-A Antigens | 6 | 1.0 |
HLA-DR5 Antigen | 3 | 18.0 |
Rheumatic Diseases/*genetics/immunology | 2 | 66.0 |
HLA-B35 Antigen | 2 | 8.0 |
HLA Antigens/analysis/genetics | 3 | 11.0 |
DNA Restriction Enzymes/diagnostic use | 3 | 8.0 |
HLA Antigens/*analysis/immunology | 2 | 11.0 |
HLA-C Antigens | 6 | 4.0 |
Antibodies, Monoclonal/physiology | 2 | 2.0 |
Carbohydrate Conformation | 2 | 1.0 |
Concanavalin A | 2 | 4.0 |
HLA-DQ Antigens | 6 | 18.0 |
*Plant Lectins | 2 | 1.0 |
Sialic Acids | 2 | 33.0 |
Histocompatibility Antigens Class II/*analysis | 10 | 8.0 |
Corticotropin/diagnostic use | 2 | 9.0 |
Immune Sera | 2 | 0.0 |
Arthritis, Juvenile Rheumatoid/*immunology | 2 | 10.0 |
Histocompatibility Antigens Class II/genetics/*immunology | 5 | 17.0 |
Radioimmunoassay | 3 | 0.0 |
HLA-DP Antigens | 2 | 8.0 |
Antibodies, Viral/*biosynthesis | 2 | 9.0 |
*Lymphocyte Cooperation | 2 | 7.0 |
Isoelectric Point | 3 | 2.0 |
Histocompatibility Antigens Class II/immunology | 6 | 3.0 |
Reverse Transcriptase Polymerase Chain Reaction | 2 | 0.0 |
*Adrenal Hyperplasia, Congenital/*genetics | 2 | 28.0 |
Chemistry | 2 | 0.0 |
Glomerulonephritis/*genetics/pathology | 2 | 66.0 |
Immunoglobulin A/*immunology | 2 | 7.0 |
Kidney Glomerulus/pathology | 2 | 4.0 |
HLA-A2 Antigen | 2 | 6.0 |
